Drilldown: Medicines
More actions
Medicines > classes 
:
Anticonvulsant or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]]
:
Anticonvulsant or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] Use the filters below to narrow your results.
generic:
Brivaracetam (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fosphenytoin (1) ·
Lacosamide (1) ·
Mirabegron (1) ·
Oxybutynin (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rufinamide (1) ·
Solifenacin (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Luminal (1) ·
Myrbetriq (1) ·
Onfi (1) ·
Sabril (1) ·
Vesicare (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)
uses:
starting dose:
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (19) ·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)
pregnancy:
Showing below up to 22 results in range #1 to #22.